Patient Education
Share your love
Chronic nAMD With Cataract Complications: Visual Stabilization Through Sequential Anti-VEGF Strategies | Ophthalmology Times
Treatment-Resistant Retinal Disease Management With Sequential Anti-VEGF Strategies This comprehensive presentation examines complex retinal disease management using sequential anti-VEGF therapies, supported by pharmacokinetic modeling from 17 aflibercept trials involving 2700 individuals. The data demonstrates that aflibercept 8 mg exhibits 34.4%…
Treatment-Resistant AMD Achieving Anatomical and Functional Gains With Aflibercept 8 mg | Ophthalmology Times
Treatment-Resistant AMD and Diabetic Macular EdemaWith High-Dose Aflibercept Summary This presentation examines the management of treatment-resistant retinal conditions using high-dose aflibercept, focusing on cases where standard anti-VEGF therapy has failed to achieve optimal outcomes. The session includes pharmacokinetic modeling data…
DME Management With Transition to High-Dose Aflibercept Following Suboptimal Response to Standard Anti-VEGF Therapy | Ophthalmology Times
DME Management With High-Dose Aflibercept Summary This presentation discusses DME management, focusing on transitioning to high-dose aflibercept following suboptimal responses to standard anti-VEGF therapy. The session was part of a Case-Based Roundtable meeting held in conjunction with the American Society…
Vizz officially launches in the United States | Ophthalmology Times
(Image Credit: AdobeStock) Following a US Food and Drug Administration approval back in July 2025, LENZ Therapeutics has announced that VIZZ (aceclidine ophthalmic solution) 1.44% is now commercially available.1 The first and only FDA-approved aceclidine-based eye drop is for the…
David Lally discusses the ARCHER trial and the optimistic outcomes fueling future research | Ophthalmology Times
Note: Video captions are generated with the assistance of AI and may contain errors. David Lally, MD, presented at the 2025 Retina Society meeting, discussing the ARCHER study (NCT04656561) of ANX007 for the treatment of age-related macular degeneration (AMD) and…
Q&A: Mario Romano discusses temperature during vitrectomy | Ophthalmology Times
Photo of Mario Romano at EURETINA 2025 Mario Romano, MD, PhD, a researcher from Humanitas University in Italy, discusses work on temperature control during vitrectomy. His research, supported by the Italian Ministry of Research, reveals significant temperature drops during eye…
Lupin signs definitive agreement to acquire VISUfarma | Ophthalmology Times
(Image Credit: AdobeStock/Rido) Lupin’s subsidiary, Nanomi, has signed a definitive agreement to acquire VISUfarma, a portfolio company of GHO Capital Partners LLP. Lupin notes that the acquisition will help the company expand its European business, as well as advance the…
Q&A: Nadia Waheed on the role of OCT in the future of ophthalmology | Ophthalmology Times
Photo of Nadia Waheed at the 2025 EURETINA meeting held in Paris, France Ultra High Resolution OCT is revolutionizing retinal imaging, offering unprecedented insights into eye diseases. Nadia Waheed, MD, MPH, from Tufts University School of Medicine discusses how this…
Positive pediatric data emerge from the OPGx-LCA5 phase 1/2 trial of Leber congenital amaurosis type 5 | Ophthalmology Times
Image credit: AdobeStock/arturkowynia Opus Genetics today announced the positive 3-month pediatric data from its Phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5, an investigational gene therapy for Leber congenital amaurosis type 5 (LCA5), an ultra-rare form…
Q&A: Patricio Schlottmann discusses results of AVONELLE-X faricimab extension trial | Ophthalmology Times
Photo of Patricio Schlottmann at the 2025 EURETINA meeting in Paris, France Patricio Schlottmann, MD, a retina specialist from Buenos Aires, Argentina, discusses the AVONELLE-X extension study of faricimab, a treatment for wet age-related macular degeneration (AMD). The study, spanning…